Post Coronavirus Disease (COVID-19) Syndrome Indonesian Population

• Sponsor: Hasanuddin University (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT05060562
• Collaborator: Chulalongkorn University (Other)
• Enrollment: 1,152
• Locations: 2
• Anticipated Duration (Months): 17.5
• Patients Per Site: 576
• Patients Per Site Per Month: 33

Study Details

Study Description

Brief Summary

Background and Objective Persistent symptoms after COVID 19 episodes (or referred to as Long COVID) can appear at a certain period and affect the quality of life of the patients, as well as introduce other comorbidities. It is important to address the associated factors of persistent symptoms after the COVID 19 episode. By identifying these factors, a screening method could be deployed to detect individuals that are prone to persistent COVID 19 symptoms.

Method:

This cohort study recruit COVID 19 patients at all stages in Indonesia (including people who underwent home isolation). Patient-based clinical information is collected from the patient including the demographic information, general health status, COVID 19 vaccination, and COVID 19 treatment. The outcome is the occurrence of persistent COVID 19-related symptoms after being declared as cured. A logistic regression model and Cox Regression are applied to the model to find the associated factors. Machine learning and Deep Learning model will be constructed and deployed into a web-based application for a further screening program.

Hypothesis:

1. There is an association between duration of COVID episode, repeated COVID episode, and the presence of persistent COVID 19 Symptoms

2. Vaccinated individual who was infected with Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (COV2) will have less persistent COVID 19 symptoms

3. Individuals with comorbidities are prone to persistent COVID 19 Symptoms

4. Appropriate medications (including early administration of antiviral therapy) lead to a lower probability of persistent COVID 19 Symptoms

Condition or Disease	Intervention/Treatment	Phase
Covid19	Other: COVID 19 positive; Other: COVID 19 negative

Detailed Description

Target Population:

As explained in the study population section

Recruitment

1. Snowball technique from the COVID 19 survivor groups

2. Online questionnaire is provided to obtain the data

Data Source:

1. Medical Resume

2. Laboratory Information possessed by individuals

3. Telemedicine observation possessed by individuals

Predictors:

1. Demographic factors (age at diagnosis and current age at data collection, sex at birth, occupation, education, province of domicile, and possession of health insurance during COVID 19 infection)

2. General health status (Body Mass Index, presence of chronic disease and comorbidities, smoking, alcohol drinking, moderate physical activity)

3. History of COVID 19 vaccination (date, type of vaccine, booster dose, side effect, and medication following the vaccination)

4. COVID 19 episode (date of diagnosis, method of diagnosis confirmation, history of suspected SARS COV2 reinfection, Cycle-Threshold (CT) value, the symptoms and duration of the symptoms, medication, oxygen supplementation, hospitalization, or receiving plasma convalescent therapy)

List of persistent COVID 19 symptoms in this study (and not limited to)

1. Neurological and Psychiatric symptoms

• Anxiety

• Depression

• Sleep disturbances

• PTSD

• Cognitive impairment

1. Ear Nose Throat symptoms

• Persistent anosmia

• Persistent ageusia

• Tinnitus and other hearing disorders

1. Respiratory Symptoms

• Chronic cough

• Shortness of breath

1. Cardiovascular symptoms

• Peripheral artery disease

• New onset of arrhythmia

• Carditis (either pericarditis or myocarditis)

1. Hematological symptoms

• Thromboembolic event

1. Renal Disorder

• Reduced filtration function

1. Musculoskeletal disorder

• Chronic fatigue

• Joint pain

• Muscular pain

1. Dermatology disorder

• Rash

• Hair loss

1. Gastrointestinal disorder

• Chronic Diarrhea

• Irritable Bowel Syndrome

Study Size

1. The one-sample proportion formula

2. Type I error value as 5%.

3. The prevalence of COVID 19 in Indonesia is 1%

4. Absolute value of margin of error set as 0.5%

5. the total sample needed is 1152 participants.

Proposed Statistical Analysis

1. Data cleaning was conducted

2. No imputation to missing data

3. Descriptive statistics and normality tests

4. Logistic regression to analyze the associated factors of each outcome followed by estimating the adjusted odds ratio.

5. The time-to-event analysis for post COVID symptoms was conducted in a certain subgroup of the variables using the cox regression model.

6. Neural Network model and deployment into a web-based application

Study Design

• Study Type: Observational
• Anticipated Enrollment: 1152 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Predictors of the Occurrence of Post Coronavirus Disease Syndrome Among COVID-19 Patients in Indonesia
• Actual Study Start Date: Sep 1, 2021
• Anticipated Primary Completion Date: Dec 1, 2022
• Anticipated Study Completion Date: Feb 15, 2023

Arms and Interventions

Arm	Intervention/Treatment
Post COVID 19 symptoms Positive The presence of persistent COVID-related symptoms after being cured.	Other: COVID 19 positive; Diagnosed as COVID 19 patient using Real-Time Polymerase Chain Reaction (RT-PCR) with the nasopharyngeal swab, or Rapid Antigen test of nasopharyngeal swab with suggestive symptoms.; Other: COVID 19 negative; Suspected COVID 19 patients who were tested negative using either Real-Time Polymerase Chain Reaction (RT-PCR) with the nasopharyngeal swab, or Rapid Antigen test of nasopharyngeal swab.
Post COVID 19 symptoms Negative No persistent COVID-related symptoms after cured	Other: COVID 19 positive; Diagnosed as COVID 19 patient using Real-Time Polymerase Chain Reaction (RT-PCR) with the nasopharyngeal swab, or Rapid Antigen test of nasopharyngeal swab with suggestive symptoms.; Other: COVID 19 negative; Suspected COVID 19 patients who were tested negative using either Real-Time Polymerase Chain Reaction (RT-PCR) with the nasopharyngeal swab, or Rapid Antigen test of nasopharyngeal swab.

Outcome Measures

Primary Outcome Measures

1. Presence of post COVID 19 Symptoms two weeks [within two weeks after declared cured]

   Any COVID-related symptoms persist after declared cured. Defined as a binary response, yes or no

2. Presence of post COVID 19 Symptoms four weeks [within four weeks after declared cured]

   Any COVID-related symptoms persist after declared cured. Defined as a binary response, yes or no

3. Presence of post COVID 19 Symptoms eight weeks [within eight weeks after declared cured]

   Any COVID-related symptoms persist after declared cured. Defined as a binary response, yes or no

4. Presence of post COVID 19 Symptoms twelve weeks [within twelve weeks after declared cured]

   Any COVID-related symptoms persist after declared cured. Defined as a binary response, yes or no

5. Presence of post COVID 19 Symptoms six months [within six months after declared cured]

   Any COVID-related symptoms persist after declared cured. Defined as a binary response, yes or no

Secondary Outcome Measures

1. Presence of post COVID 19 Symptoms among vaccinated individual diagnosed with COVID 19 [within six months after declared cured]

   Any COVID-related symptoms persist after declared cured among vaccinated individual. Defined as a binary response, yes or no

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion criteria

1. Age above 18 years old

2. Diagnosed as Coronavirus Disease 2019 by RT- PCR, or Rapid Antigen

Exclusion Criteria

1. Unable to retrieve information regarding the persistent symptoms

2. Died within six months after declared as cured

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Khairun University Faculty of Medicine	Ternate	North Maluku	Indonesia
2	Hasanuddin University Medical Research Center / HUMRC	Makasar	South Sulawesi	Indonesia	90245

Sponsors and Collaborators

• Hasanuddin University
• Chulalongkorn University

Investigators

• Principal Investigator: Bumi Herman, M.D Ph.D, Chulalongkorn University
• Study Director: Sathirakorn Pongpanich, Ph.D, Chulalongkorn University
• Principal Investigator: Pramon Viwattanakulvanid, Ph.D, Chulalongkorn University

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

• Questionnaire in Indonesian language

Publications

• Ahmed H, Patel K, Greenwood DC, Halpin S, Lewthwaite P, Salawu A, Eyre L, Breen A, O'Connor R, Jones A, Sivan M. Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis. J Rehabil Med. 2020 May 31;52(5):jrm00063. doi: 10.2340/16501977-2694.
• Carfì A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020 Aug 11;324(6):603-605. doi: 10.1001/jama.2020.12603.
• Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020 Aug 11;370:m3026. doi: 10.1136/bmj.m3026.
• Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, Kang L, Guo L, Liu M, Zhou X, Luo J, Huang Z, Tu S, Zhao Y, Chen L, Xu D, Li Y, Li C, Peng L, Li Y, Xie W, Cui D, Shang L, Fan G, Xu J, Wang G, Wang Y, Zhong J, Wang C, Wang J, Zhang D, Cao B. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021 Jan 16;397(10270):220-232. doi: 10.1016/S0140-6736(20)32656-8. Epub 2021 Jan 8.
• Hui DS, Joynt GM, Wong KT, Gomersall CD, Li TS, Antonio G, Ko FW, Chan MC, Chan DP, Tong MW, Rainer TH, Ahuja AT, Cockram CS, Sung JJ. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax. 2005 May;60(5):401-9.
• Jacobs LG, Gourna Paleoudis E, Lesky-Di Bari D, Nyirenda T, Friedman T, Gupta A, Rasouli L, Zetkulic M, Balani B, Ogedegbe C, Bawa H, Berrol L, Qureshi N, Aschner JL. Persistence of symptoms and quality of life at 35 days after hospitalization for COVID-19 infection. PLoS One. 2020 Dec 11;15(12):e0243882. doi: 10.1371/journal.pone.0243882. eCollection 2020.
• Lam MH, Wing YK, Yu MW, Leung CM, Ma RC, Kong AP, So WY, Fong SY, Lam SP. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Arch Intern Med. 2009 Dec 14;169(22):2142-7. doi: 10.1001/archinternmed.2009.384.
• Lee SH, Shin HS, Park HY, Kim JL, Lee JJ, Lee H, Won SD, Han W. Depression as a Mediator of Chronic Fatigue and Post-Traumatic Stress Symptoms in Middle East Respiratory Syndrome Survivors. Psychiatry Investig. 2019 Jan;16(1):59-64. doi: 10.30773/pi.2018.10.22.3. Epub 2019 Jan 7.
• Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC Neurol. 2011 Mar 24;11:37. doi: 10.1186/1471-2377-11-37.
• Moreno-Pérez O, Merino E, Leon-Ramirez JM, Andres M, Ramos JM, Arenas-Jiménez J, Asensio S, Sanchez R, Ruiz-Torregrosa P, Galan I, Scholz A, Amo A, González-delaAleja P, Boix V, Gil J; COVID19-ALC research group. Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study. J Infect. 2021 Mar;82(3):378-383. doi: 10.1016/j.jinf.2021.01.004. Epub 2021 Jan 12.
• Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021 Jan 22;372:n136. doi: 10.1136/bmj.n136. Erratum in: BMJ. 2022 Jan 19;376:o126.

• Responsible Party: Bumi Herman, Assistant Lecturer, Hasanuddin University
• ClinicalTrials.gov Identifier: NCT05060562
• Other Study ID Numbers: 1407212101
• First Posted: Sep 29, 2021
• Last Update Posted: Jul 20, 2022
• Last Verified: Jul 1, 2022

• Individual Participant Data (IPD) Sharing Statement: Undecided
• Plan to Share IPD: Undecided
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Bumi Herman, Assistant Lecturer, Hasanuddin University: COVID 19; Post COVID 19 symptoms
• Additional relevant MeSH terms: COVID-19

Study Results

No Results Posted as of Jul 20, 2022